Muz Mansuri joined F-Prime Capital in January 2020 as a Venture Partner and is based in the Boston office. Muz will be working with various F-Prime team members to evaluate therapeutic and digital investment and company creation opportunities. Muz has more than 35 years of experience in various R&D roles as a senior executive within the global biopharmaceutical industry.

Prior to joining F-Prime, Muz was a member of the Executive Committee at Sanofi, as Executive Vice President, Strategy, Business Development, and Licensing.  Among other responsibilities, Muz headed the Strategy, Business Development, Alliance Management and the Venture Group for Sanofi.  Before this, he was at Gilead Sciences as Senior Vice President, Research and Development Strategy and Business Development.  In that capacity he led the R&D Strategy, Business Development, and M&A activities for the company.  Muz has served as Chief Executive Officer of several biotech companies and as a General Partner at Flagship Ventures (now Flagship Pioneering).  He began his career in the pharmaceutical industry as a bench medicinal chemist with Bristol Myers.

Muz received his B.Sc. and Ph.D. in Chemistry from the University College London. He conducted postdoctoral research at UCLA and Columbia University.


  • CHARM Therapeutics is a 3D deep-learning research Company discovering and developing transformational medicines. Based on the award-winning discoveries of David Baker in protein-folding, CHARM has developed a proprietary technology based on the first rapid, accurate protein/ligand co-folding algorithm. The Company’s mission is to use these insights to address challenging targets in cancer and other disease areas and discover and develop new drugs against these targets. Learn more at www.charmtx.com.


  • Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. For more information, please visit us at www.metsera.com.

  • Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research to better understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Learn more at www.xaira.com.